Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

116 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Health economics and patient outcomes of hematopoietic stem cell transplantation versus disease-modifying therapies for relapsing remitting multiple sclerosis in the United States of America.
Burt RK, Tappenden P, Han X, Quigley K, Arnautovic I, Sharrack B, Snowden JA, Hartung D. Burt RK, et al. Among authors: tappenden p. Mult Scler Relat Disord. 2020 Oct;45:102404. doi: 10.1016/j.msard.2020.102404. Epub 2020 Jul 17. Mult Scler Relat Disord. 2020. PMID: 32731201 Free article.
Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis.
Chilcott J, McCabe C, Tappenden P, O'Hagan A, Cooper NJ, Abrams K, Claxton K, Miller DH; Cost Effectiveness of Multiple Sclerosis Therapies Study Group. Chilcott J, et al. Among authors: tappenden p. BMJ. 2003 Mar 8;326(7388):522; discussion 522. doi: 10.1136/bmj.326.7388.522. BMJ. 2003. PMID: 12623909 Free PMC article.
Evaluating the clinical effectiveness of autologous haematopoietic stem cell transplantation versus disease-modifying therapy in multiple sclerosis using a matching-adjusted indirect comparison: an exploratory study from the Autoimmune Diseases Working Party (ADWP) of the European Society of Bone and Marrow Transplantation (EBMT).
Tappenden P, Wang Y, Sharrack B, Burman J, Kazmi M, Saccardi R, Bermejo I, Harvey R, Badoglio M, Farge D, Snowden JA. Tappenden P, et al. Bone Marrow Transplant. 2020 Jul;55(7):1473-1475. doi: 10.1038/s41409-019-0747-2. Epub 2019 Nov 19. Bone Marrow Transplant. 2020. PMID: 31745252 No abstract available.
116 results